IP Verse

Anavex Life Sciences competitive analysis

Loading summary...

Latest patents of Anavex Life Sciences opposed by its competitors

Explore Anavex Life Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3324956
Nov 20, 2024Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor1
EP3407880
Aug 17, 2022Neurodevelopmental Disorder Therapy1

Latest publications and patents of Anavex Life Sciences New

Explore the latest publications and patents granted to Anavex Life Sciences, showcasing their recent innovations and technological advancements.

Last updated on: Oct 19, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Anavex Life Sciences

EP3324956
Nov 20, 2024Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 ReceptorGranted And Under Opposition
EP3407880
Aug 17, 2022Neurodevelopmental Disorder TherapyOpposition Rejected

Latest PTAB cases involving Anavex Life Sciences

Discover the latest PTAB cases involving Anavex Life Sciences, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Anavex Life Sciences with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ANAVEX LIFE SCIENCES - 2 - -
ELKINGTON AND FIFE91 - - -
SANDOZ1181619 -